Editorial
Academic or non-academic: should we really pick one?
Translational Lung Cancer Research
2023;
12
(11)
:2148-2150
.
(30 November 2023)
RELAY phase 3 randomized study: a step closer to the clinic for ctDNA in non-small cell lung cancer treatment monitoring?
Translational Lung Cancer Research
2023;
12
(11)
:2151-2156
.
(30 November 2023)
Original Article
Residual tumor descriptors proposed by the International Association for the Study of Lung Cancer may not be applicable to stage I and ground-glass opacity-featured non-small cell lung cancer
Translational Lung Cancer Research
2023;
12
(11)
:2157-2168
.
(30 November 2023)
Identifying factors causing failure of nodal staging by endobronchial ultrasound-guided transbronchial needle aspiration in non-small cell lung cancer
Translational Lung Cancer Research
2023;
12
(11)
:2169-2180
.
(30 November 2023)
Pathological and radiological T descriptors in invasive lung adenocarcinoma: from correlations to prognostic significance
Translational Lung Cancer Research
2023;
12
(11)
:2181-2192
.
(30 November 2023)
Seven preoperative factors have strong predictive value for postoperative pneumonia in patients undergoing thoracoscopic lung cancer surgery
Translational Lung Cancer Research
2023;
12
(11)
:2193-2208
.
(30 November 2023)
A retrospective comparative cohort study: concurrent versus consolidative immunotherapy with chemoradiotherapy in EGFR- or ALK-negative unresectable stage III non-small cell lung cancer
Translational Lung Cancer Research
2023;
12
(11)
:2209-2218
.
(30 November 2023)
Comparison of lobectomy performed through Toumai® surgical robot and da Vinci surgical robot in early-stage non-small cell lung cancer: a retrospective study of early perioperative results
Translational Lung Cancer Research
2023;
12
(11)
:2219-2228
.
(30 November 2023)
Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer: a Chinese, multicenter, real-world cohort study
Translational Lung Cancer Research
2023;
12
(11)
:2229-2244
.
(30 November 2023)
Microbiota modulate lung squamous cell carcinoma lymph node metastasis through microbiota-geneset correlation network
Translational Lung Cancer Research
2023;
12
(11)
:2245-2259
.
(30 November 2023)
Impact of chronic obstructive pulmonary disease on lung cancer symptom burden: a population-based study in Ontario, Canada
Translational Lung Cancer Research
2023;
12
(11)
:2260-2274
.
(30 November 2023)
Real-world first-line afatinib for advanced EGFR mutation-positive non-small cell lung cancer in Korea: updated survival data
Translational Lung Cancer Research
2023;
12
(11)
:2275-2282
.
(30 November 2023)
Robotic-assisted navigation system for preoperative lung nodule localization: a pilot study
Translational Lung Cancer Research
2023;
12
(11)
:2283-2293
.
(30 November 2023)
PFKP confers chemoresistance by upregulating ABCC2 transporter in non-small cell lung cancer
Translational Lung Cancer Research
2023;
12
(11)
:2294-2309
.
(30 November 2023)
Review Article
The landscape of immune therapy in vulnerable patients with advanced non-small cell lung cancer: a narrative review
Translational Lung Cancer Research
2023;
12
(11)
:2310-2321
.
(30 November 2023)
Case Report: iMDT Corner
Adjuvant crizotinib treatment selected by patient-derived organoids in a patient with stage IIIA adenocarcinoma with novel LRRTM4-ALK fusion: a case report
Translational Lung Cancer Research
2023;
12
(11)
:2322-2329
.
(30 November 2023)
Long-term survival after stereotactic body radiotherapy combined with immunotherapy plus anti-angiogenesis therapy in patients with advanced non-small cell lung cancer and EGFR exon 20 insertion mutation: a report of two cases
Translational Lung Cancer Research
2023;
12
(11)
:2330-2341
.
(30 November 2023)
Case Report
Primary resistance to ALK inhibitors in KLC1/ALK-rearranged pleural metastatic lung adenocarcinoma: a case report
Translational Lung Cancer Research
2023;
12
(11)
:2342-2346
.
(30 November 2023)
Editorial Commentary
The opportunities and challenges of perioperative therapy of localized non-small cell lung cancer—thoughts from the KEYNOTE-671 trial
Translational Lung Cancer Research
2023;
12
(11)
:2347-2352
.
(30 November 2023)
Bringing immune-checkpoint inhibitors earlier in the management of non-small cell lung cancer
Translational Lung Cancer Research
2023;
12
(11)
:2353-2358
.
(30 November 2023)
The beginning of the perioperative immunotherapy era in early-stage non-small cell lung cancer
Translational Lung Cancer Research
2023;
12
(11)
:2359-2365
.
(30 November 2023)
